Cingulate Inc. (CING) stock
CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
$4.49−0.15 (-3.23%)
Close on Nov 12, 2026Market cap $65.29MP/E –Yield –
Cingulate operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cingulate's operating cash flow for the twelve months ending Jun 30, 2026 was -$20.65M. For fiscal 2025 it was -$17.25M. The highest annual figure on record is -$6.81M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.25M | – |
| FY2024 | Dec 31, 2024 | -$18.45M | – |
| FY2023 | Dec 31, 2023 | -$15.03M | – |
| FY2022 | Dec 31, 2022 | -$15.88M | – |
| FY2021 | Dec 31, 2021 | -$10.43M | – |
| FY2020 | Dec 31, 2020 | -$6.81M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.67M | – |
See a number that looks wrong?